No Evidence That Soluble TACI Induces Signalling via Membrane-Expressed BAFF and APRIL in Myeloid Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Nys, Josquin ^a   Smulski, Cristian R ^a   Tardivel, Aubry ^a   Willen, Laure ^a   Kowalczyk, Christine ^a   Donzé, Olivier ^b   Huard, Bertrand ^b,c   Hess, Henry ^d   Schneider, Pascal ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d Merck Serono GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; FC RECEPTOR; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL ACTIVATION; CELL SPECIFICITY; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFLAMMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOREGULATION; MACROPHAGE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR BINDING; REVERSE SIGNALING; SIGNAL TRANSDUCTION;

ANIMALS; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; CELL MEMBRANE; CHROMATOGRAPHY, GEL; HEK293 CELLS; HUMANS; MACROPHAGES; MICE; MYELOID CELLS; RECEPTORS, FC; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SOLUBILITY; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84876435574     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061350     Document Type: Article

References (54)

1. Bodmer JL, Schneider P, Tschopp J, (2002) The molecular architecture of the TNF superfamily. Trends Biochem Sci 27: 19-26.
2. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, et al. (2003) Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 198: 937-945.
3. Mackay F, Schneider P, (2009) Cracking the BAFF code. Nat Rev Immunol 9: 491-502.
4. Mohr E, Serre K, Manz RA, Cunningham AF, Khan M, et al. (2009) Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature. J Immunol 182: 2113-2123.
5. Mackay F, Schneider P, (2008) TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 19: 263-276.
6. von Bulow GU, van Deursen JM, Bram RJ, (2001) Regulation of the T-independent humoral response by TACI. Immunity 14: 573-582.
7. Mantchev GT, Cortesao CS, Rebrovich M, Cascalho M, Bram RJ, (2007) TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens. J Immunol 179: 2282-2288.
8. Benson MJ, Dillon SR, Castigli E, Geha RS, Xu S, et al. (2008) Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180: 3655-3659.
9. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199: 91-98.
10. Bossen C, Cachero TG, Tardivel A, Ingold K, Willen L, et al. (2008) TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 111: 1004-1012.
11. Sun M, Fink PJ, (2007) A new class of reverse signaling costimulators belongs to the TNF family. J Immunol 179: 4307-4312.
12. Jeon ST, Kim WJ, Lee SM, Lee MY, Park SB, et al. (2010) Reverse signaling through BAFF differentially regulates the expression of inflammatory mediators and cytoskeletal movements in THP-1 cells. Immunol Cell Biol 88: 148-156.
13. Lee SM, Jeon ST, Suk K, Lee WH, (2010) Macrophages express membrane bound form of APRIL that can generate immunomodulatory signals. Immunology 131: 350-356.
14. Lee SM, Kim WJ, Suk K, Lee WH, (2010) Cell to Cell Interaction Can Activate Membrane-bound APRIL Which Are Expressed on Inflammatory Macrophages. Immune Netw 10: 173-180.
15. Diaz-de-Durana Y, Mantchev GT, Bram RJ, Franco A, (2006) TACI-BLyS signaling via B-cell-dendritic cell cooperation is required for naive CD8+ T-cell priming in vivo. Blood 107: 594-601.
16. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, et al. (2007) Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56: 4142-4150.
17. Warnatz K, Salzer U, Rizzi M, Fischer B, Gutenberger S, et al. (2009) B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A 106: 13945-13950.
18. Hartung HP, Kieseier BC, (2010) Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord 3: 205-216.
19. Cachero TG, Schwartz IM, Qian F, Day ES, Bossen C, et al. (2006) Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor). Biochemistry 45: 2006-2013.
20. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, et al. (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260-263.
21. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, et al. (2001) Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97: 198-204.
22. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, et al. (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189: 1747-1756.
23. Bossen C, Tardivel A, Willen L, Fletcher CA, Perroud M, et al. (2011) Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses. Eur J Immunol 41: 787-797.
24. Bruhns P, (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119: 5640-5649.
25. Pelletier M, Thompson JS, Qian F, Bixler SA, Gong D, et al. (2003) Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. J Biol Chem 278: 33127-33133.
26. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, et al. (2006) Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 281: 13964-13971.
27. Nimmerjahn F, Ravetch JV, (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34-47.
28. Sanchez-Mejorada G, Rosales C, (1998) Fcgamma receptor-mediated mitogen-activated protein kinase activation in monocytes is independent of Ras. J Biol Chem 273: 27610-27619.
29. Auwerx J, Staels B, Van Vaeck F, Ceuppens JL, (1992) Changes in IgG Fc receptor expression induced by phorbol 12-myristate 13-acetate treatment of THP-1 monocytic leukemia cells. Leuk Res 16: 317-327.
30. Anderson P, Caligiuri M, O'Brien C, Manley T, Ritz J, et al. (1990) Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci U S A 87: 2274-2278.
31. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV, (2008) Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 105: 19571-19578.
32. Ono M, Yuasa T, Ra C, Takai T, (1999) Stimulatory function of paired immunoglobulin-like receptor-A in mast cell line by associating with subunits common to Fc receptors. J Biol Chem 274: 30288-30296.
33. Takai T, (2002) Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2: 580-592.
34. Vidarsson G, Stemerding AM, Stapleton NM, Spliethoff SE, Janssen H, et al. (2006) FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood 108: 3573-3579.
35. Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, et al. (2008) CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 29: 771-781.
36. Fluhrer R, Grammer G, Israel L, Condron MM, Haffner C, et al. (2006) A gamma-secretase-like intramembrane cleavage of TNFalpha by the GxGD aspartyl protease SPPL2b. Nat Cell Biol 8: 894-896.
37. Friedmann E, Hauben E, Maylandt K, Schleeger S, Vreugde S, et al. (2006) SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. Nat Cell Biol 8: 843-848.
38. Kirkin V, Cahuzac N, Guardiola-Serrano F, Huault S, Luckerath K, et al. (2007) The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells. Cell Death Differ 14: 1678-1687.
39. Sun M, Ames KT, Suzuki I, Fink PJ, (2006) The cytoplasmic domain of Fas ligand costimulates TCR signals. J Immunol 177: 1481-1491.
40. Bischof D, Elsawa SF, Mantchev G, Yoon J, Michels GE, et al. (2006) Selective activation of TACI by syndecan-2. Blood 107: 3235-3242.
41. Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, et al. (2010) Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 62: 201-210.
42. Nestorov I, Papasouliotis O, Pena Rossi C, Munafo A, (2010) Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci 99: 524-538.
43. Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, et al. (2009) An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18: 547-555.
44. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, et al. (2008) Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 58: 61-72.
45. Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr, (1996) Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 184: 2271-2278.
46. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM, (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3: 944-950.
47. Mauri C, Gray D, Mushtaq N, Londei M, (2003) Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 197: 489-501.
48. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, et al. (2008) A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28: 639-650.
49. Yang M, Sun L, Wang S, Ko KH, Xu H, et al. (2010) Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J Immunol 184: 3321-3325.
50. Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, et al. (2004) APRIL-deficient mice have normal immune system development. Mol Cell Biol 24: 997-1006.
51. Park SY, Ueda S, Ohno H, Hamano Y, Tanaka M, et al. (1998) Resistance of Fc receptor- deficient mice to fatal glomerulonephritis. J Clin Invest 102: 1229-1238.
52. Swee LK, Ingold-Salamin K, Tardivel A, Willen L, Gaide O, et al. (2009) Biological activity of ectodysplasin A is conditioned by its collagen and heparan sulfate proteoglycan-binding domains. J Biol Chem 284: 27567-27576.
53. Gross O, (2011) Measuring the inflammasome. Methods Mol Biol 844: 199-222.
54. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, et al. (1998) Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187: 1205-1213.